For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

July 16, 2026 · 1h 58m · Season 26 · Episode 283

About this episode

This episode discusses the latest advancements in the treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia, featuring insights from leading experts in oncology nursing.

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications

People in this episode

Host: Dr Kahl

Guests: Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig, Ms Mollie Moran

Topics covered

Keywords

Mentioned in this episode

Products: CD20 x CD3 Bispecific Antibodies, Polatuzumab Vedotin, Loncastuximab Tesirine, Bruton Tyrosine Kinase (BTK) Inhibitors, Bcl-2 Inhibitors

Books & works: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

More episodes of Oncology Today with Dr Neil Love

Explore listener stats, chart rankings, contacts and more on the Oncology Today with Dr Neil Love podcast page.